Patients receiving topiramate to prevent chronic migraines could potentially switch to onabotulinumtoxinA injections to reduce the frequency of their headaches, according to results of the FORWARD* study presented at the recent American Headache Society conference (AHS 2019).
Fremanezumab, a fully humanized monoclonal antibody that selectively targets calcitonin gene-related peptide, significantly reduces the number of migraine days in patients with chronic migraine (CM) or episodic migraine (EM), according to the FOCUS* study presented at AHS 2019.
An active lifestyle, regardless of vascular risk, may delay the progression of Alzheimer’s disease (AD) by slowing down cognitive decline and neurodegeneration, according to a study presented at the Alzheimer’s Association International Conference (AAIC 2019).
Incorporating yoga as a complementary therapy to standard pharmacological treatment of migraine helps reduce the frequency and intensity of headache and its impact on the lives of people with such condition, according to the CONTAIN* study presented at the 2019 AHS Meeting.
The novel small-molecule CGRP* receptor inhibitor ubrogepant was effective in relieving migraine pain and resolving the most bothersome migraine-associated symptom (MBS) regardless of prior triptan treatment, including in patients in whom triptans were ineffective, according to a pooled analysis of ACHIEVE I and II studies presented at AHS 2019.
Individuals who identify as sexual or gender minorities (SGM) appear to be at a higher risk of experiencing subjective cognitive decline (SCD) than individuals who identify as cisgender and heterosexual, according to a study presented at the Alzheimer’s Association International Conference (AAIC 2019).
Intensive glucose control for up to 72 hours was no better than standard therapy in terms of improving outcomes in hospitalized patients with hyperglycaemia and acute ischaemic stroke in the SHINE* trial, suggesting that intensive glucose control may not be useful in this setting.
Early detection, intervention and adoption of a healthy lifestyle are the key to ending dementia, according to Professor Vincent Mok of the Division of Neurology, Faculty of Medicine, Chinese University of Hong Kong.
A recent analysis of 1,289 individuals across normal, overweight and obese Body Mass Index (BMI) ranges demonstrated that higher BMI and waist circumference values were significantly associated with thinner brain cortices.